{
  "id": 5097346,
  "title": "Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks",
  "url": "https://urgent.news/2026/09/02/billionaire-portfolios-2-under-20-healthcare-stock-picks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T13:15:58.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/billionaire-portfolios-2-under-20-131558963.html"
  },
  "original_language": "en",
  "account": "Two under-$20 healthcare stocks, Viatris and BioCryst, have caught the attention of billionaire-led investors in the second quarter. Viatris (NASDAQ: VTRS), currently trading around $16 per share, has seen a slight decline in the number of billionaire funds holding its stock from 24 in the first quarter to 23 in the second. BioCryst (NASDAQ: BCRX), priced at approximately $10 a share, saw an increase in the number of funds holding its shares from 20 to 22 during the same period. The article primarily focuses on Viatris, which is up about 33% so far this year. The company manufactures and sells generic drugs and off-patent branded medicines. Viatris' revenue for Q2 rose by 4.9% year over year, and the management has raised fiscal 2026 guidance across all key metrics. The FDA recently approved Gwyn Lo, a once-weekly contraceptive patch, earlier than the set deadline, and expects to launch the product later in fiscal 2026. Additionally, a fast-acting version of meloxicam, a non-opioid painkiller, is still under review, with approval expected in the coming months. Viatris' forward non-GAAP P/E ratio is near 6.6, significantly lower than the sector median of 19.7, and its forward EV/EBITDA stands at approximately 7 compared to roughly 13. However, tariffs on Indian generics, which are largely imported by Viatris, pose a significant challenge, with many generic exemptions expiring in 2028.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}